Stem cells: Could it be TIME to abandon BMCs?

Nature Reviews Cardiology

Volumn 10, Issue 1, 2013, Pages 8-

  King, Alexandra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HUMAN; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; NOTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 84871760352     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.170     Document Type: Note

References (2)

1. Original articles Traverse, J. H. et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function and acute myocardial infarction: the TIME randomized trial. JAMA doi:10.1001/jama.2012. 28726
2. Hare, J. M. et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA doi:10.1001/jama.2012.25321